Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials
8 November 2024
Casandra E. Besse, Nolan M. Winicki, Cristian Puerta, Moises Hernandez, Jason X.-J. Yuan, Patricia A. Thistlethwaite
https://doi.org/10.1002/pul2.12450
Abstract
Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view